Oncternal Net Receivables from 2010 to 2024
ONCT Stock | USD 9.21 0.11 1.21% |
Net Receivables | First Reported 2004-03-31 | Previous Quarter 632 K | Current Value 717 K | Quarterly Volatility 8.1 M |
Check Oncternal Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncternal main balance sheet or income statement drivers, such as Depreciation And Amortization of 43.8 M, Interest Expense of 847.7 K or Other Operating Expenses of 36.2 M, as well as many exotic indicators such as Price To Sales Ratio of 38.14, Dividend Yield of 0.0 or PTB Ratio of 1.0. Oncternal financial statements analysis is a perfect complement when working with Oncternal Therapeutics Valuation or Volatility modules.
Oncternal | Net Receivables |
Latest Oncternal Therapeutics' Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Oncternal Therapeutics over the last few years. It is Oncternal Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncternal Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables | 10 Years Trend |
|
Net Receivables |
Timeline |
Oncternal Net Receivables Regression Statistics
Arithmetic Mean | 736,627 | |
Geometric Mean | 519,591 | |
Coefficient Of Variation | 46.72 | |
Mean Deviation | 281,431 | |
Median | 944,000 | |
Standard Deviation | 344,174 | |
Sample Variance | 118.5B | |
Range | 972K | |
R-Value | 0.09 | |
Mean Square Error | 126.6B | |
R-Squared | 0.01 | |
Significance | 0.76 | |
Slope | 6,724 | |
Total Sum of Squares | 1.7T |
Oncternal Net Receivables History
About Oncternal Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Oncternal Therapeutics income statement, its balance sheet, and the statement of cash flows. Oncternal Therapeutics investors use historical funamental indicators, such as Oncternal Therapeutics's Net Receivables, to determine how well the company is positioned to perform in the future. Although Oncternal Therapeutics investors may use each financial statement separately, they are all related. The changes in Oncternal Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Oncternal Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Oncternal Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Oncternal Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Net Receivables | 632 K | 600.4 K |
Check out the analysis of Oncternal Therapeutics Correlation against competitors. For more information on how to buy Oncternal Stock please use our How to Invest in Oncternal Therapeutics guide.Note that the Oncternal Therapeutics information on this page should be used as a complementary analysis to other Oncternal Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Oncternal Stock analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Stocks Directory Find actively traded stocks across global markets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |
Is Oncternal Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.33) | Revenue Per Share 0.39 | Quarterly Revenue Growth 1.803 | Return On Assets (0.49) | Return On Equity (0.87) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.